These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21531448)

  • 1. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
    Lee M; Kim SW; Nam EJ; Yim GW; Kim S; Kim YT
    Gynecol Oncol; 2011 Aug; 122(2):238-41. PubMed ID: 21531448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
    Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer.
    Ma X; Wang Y; Sheng H; Tian W; Qi Z; Teng F; Xue F
    J Obstet Gynaecol Res; 2014 Jan; 40(1):178-83. PubMed ID: 24102732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer.
    Qiu J; Yu Y; Fu Y; Ye F; Xie X; Lu W
    J Obstet Gynaecol Res; 2012 Apr; 38(4):651-7. PubMed ID: 22413879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
    Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
    Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
    Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
    Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
    Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.
    Prat A; Parera M; Peralta S; Perez-Benavente MA; Garcia A; Gil-Moreno A; Martinez-Palones JM; Roxana I; Baselga J; Del Campo JM
    Ann Oncol; 2008 Feb; 19(2):327-31. PubMed ID: 18065408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
    Huang CY; Yang YC; Wang KL; Chen TC; Chen JR; Weng CS; Chien HJ; Chang CL
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):405-9. PubMed ID: 27343324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.
    Gemer O; Oustinov N; Gdalevich M; Dubnik S; Levy R; Yachnin A; Lavie O; Ben Baruch N; Ben Arie A
    Tumori; 2013; 99(2):257-60. PubMed ID: 23748823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.